Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CDIOW
Upturn stock ratingUpturn stock rating

Cardio Diagnostics Holdings Inc (CDIOW)

Upturn stock ratingUpturn stock rating
$0.02
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: CDIOW (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $0

1 Year Target Price $0

Analysts Price Target For last 52 week
$0Target price
Low$
Current$0.02
high$

Analysis of Past Performance

Type Stock
Historic Profit -18.75%
Avg. Invested days 49
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 3.06
52 Weeks Range 0.01 - 0.18
Updated Date 05/17/2025
52 Weeks Range 0.01 - 0.18
Updated Date 05/17/2025
Dividends yield (FY) -
Basic EPS (TTM) -

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -173463.83%

Management Effectiveness

Return on Assets (TTM) -43.94%
Return on Equity (TTM) -81.24%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 1605873
Shares Outstanding -
Shares Floating 1605873
Percent Insiders -
Percent Institutions -

Analyst Ratings

Rating -
Target Price -
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Cardio Diagnostics Holdings Inc

stock logo

Company Overview

overview logo History and Background

Cardio Diagnostics Holdings Inc. is a cardiovascular precision medicine company that aims to improve prevention, detection, and management of cardiovascular disease through integrated genomics and artificial intelligence. Founded relatively recently, it has focused on developing diagnostic tests and tools leveraging AI.

business area logo Core Business Areas

  • Precision Cardiovascular Diagnostics: Focuses on developing and commercializing integrated genetic-clinical risk assessment tools to predict cardiovascular events.
  • AI-Driven Analysis: Applies artificial intelligence and machine learning to patient data for enhanced cardiac risk assessment.

leadership logo Leadership and Structure

Information regarding its leadership team and detailed organizational structure can be found on their investor relations page. This section would include names and titles such as CEO, CFO and board members along with the departments and number of staff in each one.

Top Products and Market Share

overview logo Key Offerings

  • Epi+Gen CHD: A blood-based test utilizing epigenetics and genetics to assess a patient's risk of coronary heart disease (CHD). Market share data is currently limited due to the competitive landscape with companies like Myriad Genetics and Exact Sciences. Revenue data can be sourced on their investor relations page.
  • Epi+Gen CVD: Broader cardiovascular disease risk assessment test. Market share data is currently limited due to the competitive landscape with companies like Myriad Genetics and Exact Sciences. Revenue data can be sourced on their investor relations page.

Market Dynamics

industry overview logo Industry Overview

The cardiovascular diagnostics market is growing due to aging populations, increasing prevalence of heart disease, and advancements in diagnostic technologies. Personalized medicine and AI are driving innovation.

Positioning

Cardio Diagnostics is positioned as an innovative player leveraging AI and genomics in cardiovascular risk assessment. They aim to differentiate through precision and personalized insights.

Total Addressable Market (TAM)

The global cardiovascular diagnostics market is expected to reach billions of dollars. Cardio Diagnostics aims to capture a portion of this TAM through its novel diagnostic solutions.

Upturn SWOT Analysis

Strengths

  • Proprietary AI-driven platform
  • Focus on personalized cardiovascular medicine
  • Novel epigenetic approach
  • Potential for improved diagnostic accuracy

Weaknesses

  • Limited market penetration
  • Reliance on funding
  • Relatively small company size
  • Limited revenue

Opportunities

  • Expanding market for precision medicine
  • Partnerships with healthcare providers
  • Increased adoption of AI in diagnostics
  • Development of new diagnostic tests

Threats

  • Competition from established diagnostic companies
  • Regulatory hurdles
  • Reimbursement challenges
  • Technological advancements by competitors

Competitors and Market Share

competitor logo Key Competitors

  • MYGN
  • EXAS
  • MDT

Competitive Landscape

Cardio Diagnostics competes with larger, more established diagnostic companies. Its advantage lies in its AI-driven approach and focus on precision cardiovascular medicine. Its disadvantage is its smaller size and limited market penetration.

Growth Trajectory and Initiatives

Historical Growth: Historical growth trends can be derived from the financial reports on their investor relations website.

Future Projections: Analyst estimates for future growth can be sourced from financial news outlets. Investors.com, and Yahoo Finance.

Recent Initiatives: Recent initiatives are located in press releases from the company on their investor relations page. These include partnerships and product development milestones.

Summary

Cardio Diagnostics is a relatively new company in the cardiovascular diagnostics space leveraging AI and genomics. While its AI-driven approach is promising, the company faces challenges from established competitors and needs to demonstrate sustainable growth. Its success depends on securing partnerships, expanding market reach, and achieving favorable reimbursement for its tests. The company's limited revenue and reliance on funding present significant risks.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website (Investor Relations)
  • SEC Filings
  • Financial News Outlets (e.g., Yahoo Finance, Investors.com)
  • Market Research Reports

Disclaimers:

This analysis is for informational purposes only and should not be considered investment advice. Market share data may be estimated. Financial data is based on publicly available information and may not be exhaustive. Investors should conduct their own due diligence before making investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cardio Diagnostics Holdings Inc

Exchange NASDAQ
Headquaters Chicago, IL, United States
IPO Launch date 2022-01-14
Co-Founder, CEO & Director Dr. Meeshanthini V. Dogan Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 13
Full time employees 13

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights to clinicians prescribing to help improve chronic care management. It also provides CardioInnovate360, a research-use-only solution to support the discovery, development and validation of novel biopharmaceuticals for the assessment and management of cardiovascular diseases; and HeartRisk, a SaaS cardiovascular disease risk intelligence platform. It serves telemedicine providers; provider organizations, including concierge practices, longevity clinics, and risk-bearing provider organizations; and employer organizations. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.